DelMar Pharmaceuticals, Inc. has entered into a definitive merger agreement to acquire Adgero Biopharmaceuticals, a privately held biopharmaceutical company developing its late stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications.   Upon completion of the merger, current DelMar and Adgero stockholders will own 50.5% and 49.5% of the combined company, respectively. Subject to closing conditions, the transaction is expected to close in 3Q20, at which t...